Immuron shares fall 33.77% after-hours as clinical trial for ETEC product fails primary endpoint.

Immuron Ltd (NASDAQ:IMRN) fell 33.77% in after-hours trading following the announcement that a clinical trial evaluating its ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint. The Uniformed Services University-led study, testing a third-party manufactured formulation of IMM-124E, showed no superiority over prior data supporting the company’s commercial product, Travelan®. Key factors cited included dosing timing discrepancies, participant non-compliance, and differences in administration methods compared to the approved regimen. Despite plans to proceed with an FDA End-of-Phase 2 meeting and ongoing collaborations, the trial’s failure signaled investor skepticism about the product’s efficacy. The sharp decline aligns with similar premarket drops reported globally, reflecting widespread concern over the setback.